Saturday , September 23 2017

From the Editor

September, 2017

  • 23 September

    Sept. 23, 2017

    dave

    It is kind of funny that just a little over 4 years ago the idea that the kidneys had anything to do with causing diabetes was not in the realm of medical practice. “Way back” then only the opposite was imagined: that diabetes affected the kidneys. Then Invokana was introduced ...

    Read More »

Latest Articles

September, 2017

Test Your Knowledge

Antihyperglycemic Medications for Patients with Type 2 Diabetes

The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) list a hierarchy of usage for antihyperglycemic medications after metformin. Which one of the following lists shows the correct hierarchy, beginning with the most preferred?

Correct

Correct Answer: A

Explanation: The AACE and ACE guidelines recommend individualizing treatment after metformin, but they do offer the following hierarchy: GLP-1 RAs, SGLT-2 inhibitors, DPP-4 inhibitors, TZDs, and basal insulins. GLP-1 RAs are at the top of the hierarchy because of their weight loss properties and low risk for hypoglycemia.  Inzucchi SE, et al. Diabetes Care. 2015;38(1):140-149.

Garber AJ, et al. Endocr Pract. 2016;22(1):84-113. After Metformin: Choosing the Next Hypoglycemic Medication

Incorrect

More Articles

September, 2017

  • 23 September

    Will CGMs Replace BG Monitors?

    iStock_000075170267_Small

    Do you feel that continuous blood glucose monitoring (CGM) will eventually replace blood glucose monitors? Follow the link to share your response.

    Read More »
  • 23 September

    Current Interview: Todd Hobbs

    todd-hobbs-img

    Dr. Todd Hobbs is Vice President and Chief Medical Officer for Novo Nordisk in North America, where he leads the organization’s focus on the implications of diabetes for the patient, healthcare system, and healthcare professionals. He provides overall medical guidance to Novo Nordisk’s diabetes and obesity-related projects. Prior to working at Novo Nordisk, Dr. Hobbs had established a clinical practice based in Louisville, Kentucky, focusing on the intensive management of patients with diabetes of all ages, and served as chairman of the medicine department for a large regional medical center in Kentucky. During this 10year clinical career, he cared for more than 2,500 adults and children with diabetes, including outpatient and inpatient care, as well as intensive care.

    Read More »
  • 23 September

    Todd Hobbs Transcript

    todd-hobbs-img

    Dr. Todd Hobbs discusses diabetes and obesity related projects at Novo Nordisk, including the results of the DEVOTE trial: the cardiovascular outcomes trial for degludec, basal insulin.

    Read More »
  • 23 September

    Todd Hobbs Full Interview

    todd-hobbs-img

    n this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about data from various important trials as well as the importance of their unique product degludec.

    Read More »
  • 22 September

    Todd Hobbs Part 1, Background and Introduction

    todd-hobbs-img

    In part 1 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about his work at Novo Nordisk not only as chief medical officer but also as a person with type 1.

    Read More »
  • 22 September

    Todd Hobbs Part 2, Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine

    todd-hobbs-img

    In part 2 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about DEVOTE data and how degludec works.

    Read More »
  • 22 September

    Todd Hobbs Part 3, Dual 7 Trial-Xultophy

    todd-hobbs-img

    In part 3 of this Exclusive Interview, Dr. Todd Hobbs explains the DUAL-7 data in a converstion with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

    Read More »
  • 22 September

    Todd Hobbs Part 4, GLP-1 Drug Trials

    todd-hobbs-img

    In part 4 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the GLP-1 cardiovascular trials and the significance of the LEADER study.

    Read More »
  • 22 September

    Todd Hobbs Part 5, The Future of Novo Nordisk

    todd-hobbs-img

    In part 5, the conclusion, of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about what's in the pipeline for Novo Nordisk and smart insulin.

    Read More »
  • 19 September

    Insulin for Life Answering Calls for Help

    insulinforlife

    Concerned about the extreme weather disasters we have had and those predicted, I reached out to Carol Atkinson, Director of Insulin for Life, a trusted organization, to see how we could help. She was so busy putting packages together for people who have diabetes, she quickly told me the story of Wharton, Texas. It was Labor Day weekend. Hurricane Harvey had just hit and it hit Wharton, Texas hard. They were in need of insulin.

    Read More »
  • 19 September

    Sood & Messer Part 5, Methodology of Diabetic Treatment

    Sood&Messer

    Drs. Sood and Meeser talk with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the treatment methods that have brought them the most success for their patients.

    Read More »
  • 19 September

    Albuminuria: A Lot More Than Just a Little Protein in the Urine Part 5

    iStock_000016469615_Smalldiseased kidney

    In this week's Homerun Slides, health conditions potentially indicated by albuminuria levels.

    Read More »
  • 19 September

    International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #91: Lipid and Lipoprotein Metabolism, Hypolipidemic Agents, and Therapeutic Goals Part 3

    DeFronzoCover

    In the fasting state, hepatic VLDL assembly and secretion predominate. Utilization of nascent apo B100 for the assembly and secretion of VLDL is, to a large extent, limited by substrate availability, namely TG, as apo B100 is constitutively synthesized. In the presence of adequate TG, apo B100 is progressively lipidated through the actions of hepatic MTP, and the newly assembled VLDL particle is transported to the Golgi apparatus, where it may undergo further lipidation before secretion into plasma.

    Read More »
  • 16 September

    EASD: SGLT-2/GLP-1 Combo Better Than Monotherapy

    iStock_000005179538_Small

    Trial finds improvement in control and weight loss.

    Read More »
  • 16 September

    EASD: First Oral Drug for Type 1 Diabetes – Tandem3 Study – Sotagliflozin

    iStock_000019437131_Small

    Addition to insulin therapy helped reduce hemoglobin A1c levels, researchers reported.

    Read More »